The impact of elexacaftor/tezacaftor/ivacaftor on cystic fibrosis health-related quality of life and decision-making about daily treatment regimens: a mixed methods exploratory study.

Melissa J BasileJennifer PoloKatherine HenthorneJoan DeCelie-GermanaSusan GalvinJanice Wang

Published in: Therapeutic advances in chronic disease (2024)

With little long-term data on the impact of reducing non-ETI treatments, participants weighed how they were feeling, treatment efficacy beliefs, and risk tolerance when making treatment decisions.

Keyphrases

cystic fibrosis
decision making
physical activity
pseudomonas aeruginosa
clinical trial
randomized controlled trial
machine learning
combination therapy
lung function
big data
air pollution
electronic health record